Literature DB >> 24784775

The effects of neoadjuvant chemoradiotherapy on physical fitness and morbidity in rectal cancer surgery patients.

M A West1, L Loughney2, C P Barben3, R Sripadam4, G J Kemp5, M P W Grocott6, S Jack7.   

Abstract

BACKGROUND: Neoadjuvant chemoradiotherapy (NACRT) followed by surgery for resectable locally advanced rectal cancer improves outcome compared with surgery alone. Our primary hypothesis was that NACRT impairs objectively-measured physical fitness. We also wished to explore the relationship between fitness and postoperative outcome.
METHOD: In an observational study, we prospectively studied 27 consecutive patients, of whom 25 undertook cardiopulmonary exercise testing (CPET) 2 weeks before and 7 weeks after standardized NACRT, then underwent surgery. In-hospital post-operative morbidity and mortality were recorded. Patients were followed up to 1 year for mortality. Data was analysed blind to clinical details. Receiver-operating characteristic (ROC) analysis defined the predictive value of CPET for in-hospital morbidity at day 5.
RESULTS: Oxygen uptake ( [Formula: see text] in ml kg(-1) min(-1)) at estimated lactate threshold (θˆL) and at peak exercise ( [Formula: see text] at peak in ml kg(-1) min(-1)) both significantly decreased post-NACRT: [Formula: see text] at θˆL 12.1 (pre-NACRT) vs. 10.6 (post-NACRT), p < 0.001 (95%CI -1.7, -1.2); [Formula: see text] at peak 18.1 vs. 16.7, p < 0.001 (95%CI -3.1, -1.0). Optimal [Formula: see text] at θˆL and peak pre-NACRT for predicting postoperative morbidity were 12.0 and 18.1 ( [Formula: see text] at θˆL - AUC = 0.71, 77% sensitive and 75% specific; [Formula: see text] at peak - AUC = 0.75, 78% sensitive and 76% specific). Optimal [Formula: see text] at θˆL and peak post-NACRT for predicting postoperative morbidity were 10.7 and 16.7 ( [Formula: see text] at θˆL - AUC = 0.72, 77% sensitive and 83% specific; [Formula: see text] at peak - AUC = 0.80, 85% sensitive and 83% specific).
CONCLUSION: NACRT before major rectal cancer surgery significantly decreased physical fitness as assessed by CPET. TRIALS REGISTRY NUMBER: NCT01334593.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer surgery; Cardiopulmonary exercise testing; Morbidity; Neoadjuvant chemoradiotherapy; Physical fitness; Rectal cancer

Mesh:

Substances:

Year:  2014        PMID: 24784775     DOI: 10.1016/j.ejso.2014.03.021

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  33 in total

1.  The influence of high-intensity compared with moderate-intensity exercise training on cardiorespiratory fitness and body composition in colorectal cancer survivors: a randomised controlled trial.

Authors:  James L Devin; Andrew T Sax; Gareth I Hughes; David G Jenkins; Joanne F Aitken; Suzanne K Chambers; Jeffrey C Dunn; Kate A Bolam; Tina L Skinner
Journal:  J Cancer Surviv       Date:  2015-10-19       Impact factor: 4.442

2.  Home-based exercise during preoperative therapy for pancreatic cancer.

Authors:  An Ngo-Huang; Nathan H Parker; Xuemei Wang; Maria Q B Petzel; David Fogelman; Keri L Schadler; Eduardo Bruera; Jason B Fleming; Jeffrey E Lee; Matthew H G Katz
Journal:  Langenbecks Arch Surg       Date:  2017-07-15       Impact factor: 3.445

3.  Comparison of Duke Activity Status Index with cardiopulmonary exercise testing in cancer patients.

Authors:  Michael H-G Li; Vladimir Bolshinsky; Hilmy Ismail; Kwok-Ming Ho; Alexander Heriot; Bernhard Riedel
Journal:  J Anesth       Date:  2018-05-29       Impact factor: 2.078

4.  Association between physical fitness, quality of life, and depression in stage II-III colorectal cancer survivors.

Authors:  Junga Lee; Mikyung Lee; Sunghyun Hong; Ji Young Kim; Hyuna Park; Minsuk Oh; Hyuk In Yang; Dong-Woo Kang; Jihye Park; Dong-Il Kim; Sanghee Chu; Jiwon Lee; Hyuk Hur; Nam Kyu Kim; Justin Y Jeon
Journal:  Support Care Cancer       Date:  2015-02-17       Impact factor: 3.603

Review 5.  Exercise Therapy and Cardiovascular Toxicity in Cancer.

Authors:  Jessica M Scott; Tormod S Nilsen; Dipti Gupta; Lee W Jones
Journal:  Circulation       Date:  2018-03-13       Impact factor: 29.690

6.  Perioperative Considerations in Metastatic Renal Cell Carcinoma.

Authors:  Kate Flavin; Nikhil Vasdev; Jim Ashead; Tim Lane; Damian Hanbury; Paul Nathan; Shanmugasundaram Gowrie-Mohan
Journal:  Rev Urol       Date:  2016

Review 7.  Surgeon perspectives on the use and effects of neoadjuvant chemoradiation in the treatment of rectal cancer: a comprehensive review of the literature.

Authors:  Sami A Chadi; Marianna Berho; Steven D Wexner
Journal:  Langenbecks Arch Surg       Date:  2015-08-07       Impact factor: 3.445

8.  The impact of neoadjuvant chemotherapy on cardiopulmonary physical fitness in gastro-oesophageal adenocarcinoma.

Authors:  Rcf Sinclair; M Navidi; S M Griffin; K Sumpter
Journal:  Ann R Coll Surg Engl       Date:  2016-05-03       Impact factor: 1.891

9.  Routine pre- and post-neoadjuvant chemotherapy fitness testing is not indicated for oesophagogastric cancer surgery.

Authors:  R J Drummond; D Vass; H Wadhawan; C F Craig; C K MacKay; G M Fullarton; M J Forshaw
Journal:  Ann R Coll Surg Engl       Date:  2018-04-25       Impact factor: 1.891

10.  Physical activity and exercise during preoperative pancreatic cancer treatment.

Authors:  Nathan H Parker; An Ngo-Huang; Rebecca E Lee; Daniel P O'Connor; Karen M Basen-Engquist; Maria Q B Petzel; Xuemei Wang; Lianchun Xiao; David R Fogelman; Keri L Schadler; Richard J Simpson; Jason B Fleming; Jeffrey E Lee; Gauri R Varadhachary; Sunil K Sahai; Matthew H G Katz
Journal:  Support Care Cancer       Date:  2018-10-17       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.